Nipocalimab is a fully human, anti-FcRn, aglycosylated IgG1 monoclonal antibody that reduces pathogenic alloantibodies in maternal circulation and blocks the placental transfer of maternal IgG to the ...
Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to ...
Treatment with the monoclonal antibody nipocalimab improved live birth outcomes and delayed or prevented fetal anemia or intrauterine transfusions in pregnancies at high risk for early-onset severe ...
New findings from a Phase II study indicate that antenatal treatment with the FcRn blocker nipocalimab resulted in low fetal drug exposure and transient reductions in infant IgG levels at birth, ...
Daisy Farrar loves swimming, watching Bluey, and collecting stuffed animals. Some days the four-year-old pretends to be a princess, wearing sparkly shoes and a pink dress with a tulle skirt while she ...
Johnson & Johnson (NYSE:JNJ) has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its investigational antibody therapy, nipocalimab, for hemolytic disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results